Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialLancet Oncol 2022 Oct 14;[EPub Ahead of Print], JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, RJ Francis, AY Zhang, AM Scott, ST Lee, AA Azad, MM McJannett, MR Stockler, SG Williams, ID Davis, MS Hofman
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.